The Evolving Context of Driver Mutations: ROS1 Rearrangement in Metastatic Non-Small Cell Lung Cancer

被引：0
|
作者：
DeCaire, Ximena [1 ]
Streu, Erin [1 ]
机构：
[1] CancerCare Manitoba, Winnipeg, MB, Canada
来源：
ONCOLOGY NURSING FORUM | 2016年 / 43卷 / 05期
关键词：
ambulatory care/office nursing; biotherapy/targeted therapies; clinical practice; lung cancer; CRIZOTINIB; ADENOCARCINOMA; FUSIONS;
D O I：
10.1188/16.ONF.544-547
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The discovery of driver mutations in non-small cell lung cancer (NSCLC) has led to the advent of targeted therapy and changed the clinical landscape. ROS1 is a rare driver mutation found in 1%-2% of patients diagnosed with NSCLC. This case highlights a young woman of Asian descent with no history of smoking diagnosed with NSCLC and ROS1 rearrangement and discusses the implications for oncology nurses in clinical practice.
引用
收藏
页码：544 / 547
页数：4
相关论文
共 50 条
  • [21] Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors
    Sgambato, Assunta
    Casaluce, Francesca
    Maione, Paolo
    Gridelli, Cesare
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (01) : 71 - 80
  • [22] Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF
    Zhuang, Xibin
    Zhao, Chao
    Li, Jiayu
    Su, Chunxia
    Chen, Xiaoxia
    Ren, Shengxiang
    Li, Xuefei
    Zhou, Caicun
    CANCER MEDICINE, 2019, 8 (06): : 2858 - 2866
  • [23] Patients with ROS1 rearrangement-positive non-small-cell lung cancer benefit from pemetrexed-based chemotherapy
    Song, Zhengbo
    Su, Haiyan
    Zhang, Yiping
    CANCER MEDICINE, 2016, 5 (10): : 2688 - 2693
  • [24] Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study
    Conde, Esther
    Hernandez, Susana
    Martinez, Rebeca
    Angulo, Barbara
    De Castro, Javier
    Collazo-Lorduy, Ana
    Jimenez, Beatriz
    Muriel, Alfonso
    Luis Mate, Jose
    Moran, Teresa
    Aranda, Ignacio
    Massuti, Bartomeu
    Rojo, Federico
    Domine, Manuel
    Sansano, Irene
    Garcia, Felip
    Felip, Enriqueta
    Mancheno, Nuria
    Juan, Oscar
    Sanz, Julian
    Luis Gonzalez-Larriba, Jose
    Atienza-Cuevas, Lidia
    Arriola-Arellano, Esperanza
    Abdulkader, Ihab
    Garcia-Gonzalez, Jorge
    Camacho, Carmen
    Rodriguez-Abreu, Delvys
    Teixido, Cristina
    Reguart, Noemi
    Gonzalez-Pineiro, Ana
    Lazaro-Quintela, Martin
    Dolores Lozano, Maria
    Gurpide, Alfonso
    Gomez-Roman, Javier
    Lopez-Brea, Marta
    Pijuan, Lara
    Salido, Marta
    Arriola, Edurne
    Company, Amparo
    Insa, Amelia
    Esteban-Rodriguez, Isabel
    Saiz, Monica
    Azkona, Eider
    Alvarez, Ramiro
    Artal, Angel
    Plaza, Maria Luz
    Aguiar, David
    Belen Enguita, Ana
    Benito, Amparo
    Paz-Ares, Luis
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (12) : 2120 - 2132
  • [25] Use of crizotinib as neoadjuvant therapy for non-small cell lung cancers patient with ROS1 rearrangement: A case report
    Zhao, Shikang
    Zhu, Shuai
    Lei, Xi
    Xu, Dongbo
    Shi, Tao
    Chen, Qiusong
    Ren, Fan
    Chen, Gang
    Huang, Dingzhi
    Xu, Song
    THORACIC CANCER, 2021, 12 (20) : 2815 - 2818
  • [26] Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition
    Lin, Jessica J.
    Langenbucher, Adam
    Gupta, Pranav
    Yoda, Satoshi
    Fetter, Isobel J.
    Rooney, Marguerite
    Do, Andrew
    Kem, Marina
    Chang, Kylie Prutisto
    Oh, Audris Y.
    Chin, Emily
    Juric, Dejan
    Corcoran, Ryan B.
    Dagogo-Jack, Ibiayi
    Gainor, Justin F.
    Stone, James R.
    Lennerz, Jochen K.
    Lawrence, Michael S.
    Hata, Aaron N.
    Mino-Kenudson, Mari
    Shaw, Alice T.
    NPJ PRECISION ONCOLOGY, 2020, 4 (01)
  • [27] ROS1 mutation non-small cell lung cancer-access to optimal treatment and outcomes
    Joshi, Amit
    Pande, Nikhil
    Noronha, Vanita
    Patil, Vijay
    Kumar, Rajiv
    Chougule, Anuradha
    Trivedi, Vaishakhi
    Janu, Amit
    Mahajan, Abhishek
    Prabhash, Kumar
    ECANCERMEDICALSCIENCE, 2019, 13
  • [28] Targeting ROS1 rearrangements in non-small cell lung cancer: Current insights and future directions
    Desilets, Antoine
    Repetto, Matteo
    Yang, Soo-Ryum
    Drilon, Alexander
    CANCER, 2025, 131
  • [29] Crizotinib for ROS1-rearranged non-small cell lung cancer patients
    Domblides, Charlotte
    Antoine, Martine
    Lavole, Armelle
    Cadranel, Jacques
    Wislez, Marie
    BULLETIN DU CANCER, 2017, 104 (04) : 303 - 310
  • [30] Repotrectinib: Redefining the therapeutic landscape for patients with ROS1 fusion-driven non-small cell lung cancer
    Desilets, Antoine
    Repetto, Matteo
    Drilon, Alexander
    CLINICAL AND TRANSLATIONAL MEDICINE, 2024, 14 (10):
12345